Obinutuzumab doubles remission duration in patients with relapsed, indolent non-hodgkin lymphoma

Bookmark and Share
Published: 31 May 2015
Views: 3968
Rating:
Save
Dr Laurie Helen Sehn - BC Cancer Agency, Vancouver, Canada

Dr Sehn talks to ecancertv at ASCO 2015 about a phase III study that finds that adding the new anti-CD20 monoclonal antibody obinutuzumab to standard bendamustine chemotherapy significantly delays progression of indolent non-Hodgkin lymphoma (NHL).

Read the news article and watch the press conference for more.

ecancer's filming at ASCO has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.